^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE3 inhibitor

    Related drugs:
    4d
    Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (clinicaltrials.gov)
    P=N/A, N=106, Not yet recruiting, Cairo University
    New trial
    7d
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Eyevinal (ibudilast)
    11d
    A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P2 trial
    12d
    A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=33, Completed, Verona Pharma plc | Active, not recruiting --> Completed
    Trial completion
    14d
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    14d
    Effect of levosimendan on plasma intestinal barrier factors in heart failure patients with reduced ejection fraction. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban)
    Levosimendan not only improves HF and gastrointestinal symptoms in hospitalized patients with acute exacerbation of HFrEF but also reduces plasma intestinal barrier factor levels. These effects may be associated with decreased plasma proinflammatory cytokines and increased anti-inflammatory cytokines after treatment, potentially involving IL-17 and TNF signaling pathways.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL17A (Interleukin 17A)
    18d
    The Effect of Cilostazol on Rheumatoid Arthritis Patients (clinicaltrials.gov)
    P2/3, N=70, Completed, Ain Shams University | Active, not recruiting --> Completed
    Trial completion
    |
    leflunomide
    1m
    LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 (clinicaltrials.gov)
    P3, N=540, Recruiting, Tenax Therapeutics, Inc.
    New P3 trial
    2ms
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    2ms
    Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Tanta University | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    CAPTAIN: Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage (clinicaltrials.gov)
    P3, N=316, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    2ms
    A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke (clinicaltrials.gov)
    P4, N=483, Completed, SK Chemicals Co., Ltd. | Recruiting --> Completed
    Trial completion